237 related articles for article (PubMed ID: 30862502)
1. Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion.
Rong AJ; Swaminathan SS; Vanner EA; Parrish RK
Am J Ophthalmol; 2019 Aug; 204():62-69. PubMed ID: 30862502
[TBL] [Abstract][Full Text] [Related]
2. Neovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma.
Chen HF; Chen MC; Lai CC; Yeung L; Wang NK; Chen HS; Ku WC; Wu SC; Chang SH; Chuang LH
BMC Ophthalmol; 2014 Oct; 14():119. PubMed ID: 25282154
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological evaluation and visual outcome in patients with central retinal vein occlusion, primary open-angle glaucoma and neovascular glaucoma.
Wittström E; Ponjavic V; Lövestam-Adrian M; Larsson J; Andréasson S
Acta Ophthalmol; 2010 Feb; 88(1):86-90. PubMed ID: 19432876
[TBL] [Abstract][Full Text] [Related]
4. Neovascular glaucoma in patients with central retinal vein occlusion: A real-life study in the anti-VEGF era.
Casselholm de Salles M; Lindberg C; Epstein D
Acta Ophthalmol; 2021 Feb; 99(1):e7-e12. PubMed ID: 32548981
[TBL] [Abstract][Full Text] [Related]
5. Trabeculectomy for neovascular glaucoma in proliferative diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome: Surgical outcomes and prognostic factors for failure.
Senthil S; Chary R; Ali MH; Cherukuri JR; Rani PK; Krishnamurthy R; Choudhari N; Garudadri C
Indian J Ophthalmol; 2021 Nov; 69(11):3341-3348. PubMed ID: 34708802
[TBL] [Abstract][Full Text] [Related]
6. Visual Outcomes in Eyes With Neovascular Glaucoma and Anterior Segment Neovascularization Without Glaucoma.
Sastry A; Ryu C; Jiang X; Ameri H
Am J Ophthalmol; 2022 Apr; 236():1-11. PubMed ID: 34562418
[TBL] [Abstract][Full Text] [Related]
7. A review of neovascular glaucoma. Etiopathogenesis and treatment.
Dumbrăveanu L; Cușnir V; Bobescu D
Rom J Ophthalmol; 2021; 65(4):315-329. PubMed ID: 35087972
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial.
Lorenz K; Scheller Y; Bell K; Grus F; Ponto KA; Bock F; Cursiefen C; Flach J; Gehring M; Peto T; Silva R; Tal Y; Pfeiffer N
Trials; 2017 Mar; 18(1):128. PubMed ID: 28302155
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.
Sun Y; Liang Y; Zhou P; Wu H; Hou X; Ren Z; Li X; Zhao M
BMC Ophthalmol; 2016 Aug; 16(1):150. PubMed ID: 27576739
[TBL] [Abstract][Full Text] [Related]
10. Neovascular Glaucoma: An Update.
Kalogeropoulos D; Moussa G; Sung VC; Pappa C; Kalogeropoulos C
Klin Monbl Augenheilkd; 2023 Mar; 240(3):305-315. PubMed ID: 36436509
[TBL] [Abstract][Full Text] [Related]
11. Neovascular glaucoma due to branch retinal vein occlusion combined with branch retinal artery occlusion.
An TS; Kwon SI
Korean J Ophthalmol; 2013 Feb; 27(1):64-7. PubMed ID: 23372385
[TBL] [Abstract][Full Text] [Related]
12. Predictive values of initial semi-quantitative assessment of relative afferent pupillary defect for neovascularization in central retinal vein occlusion.
Ducloyer JB; Bensaber S; Khanna RK; Cochard C; Lebreton O; Le Meur G; Lebranchu P; Arsene S; Weber M
Acta Ophthalmol; 2021 Mar; 99(2):215-220. PubMed ID: 32701208
[TBL] [Abstract][Full Text] [Related]
13. Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.
Riechardt AI; Pilger D; Cordini D; Seibel I; Gundlach E; Hager A; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2263-2269. PubMed ID: 28721444
[TBL] [Abstract][Full Text] [Related]
14. Ocular neovascularization associated with central and hemicentral retinal vein occlusion.
Hayreh SS; Zimmerman MB
Retina; 2012 Sep; 32(8):1553-65. PubMed ID: 22495331
[TBL] [Abstract][Full Text] [Related]
15. [Anti-VEGF therapy in the treatment of anterior segment neovascularization secondary to central retinal vein occlusion].
Kabesha TB; Glacet-Bernard A; Rostaqui O; Souied EH
J Fr Ophtalmol; 2015 May; 38(5):414-20. PubMed ID: 25956562
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma.
Hasanreisoglu M; Weinberger D; Mimouni K; Luski M; Bourla D; Kramer M; Robinson A; Axer-Siegel R
Eur J Ophthalmol; 2009; 19(4):607-12. PubMed ID: 19551676
[TBL] [Abstract][Full Text] [Related]
18. SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
Chan CK; Ip MS; Vanveldhuisen PC; Oden NL; Scott IU; Tolentino MJ; Blodi BA;
Ophthalmology; 2011 Jul; 118(7):1364-72. PubMed ID: 21440942
[TBL] [Abstract][Full Text] [Related]
19. [Prophylactic pan-coagulation from ischemic central vein occlusions? Practicability of the results from the Central Vein Occlusion Study Group].
Schmack I; Dithmar S
Ophthalmologe; 2003 Dec; 100(12):1062-6. PubMed ID: 14704820
[TBL] [Abstract][Full Text] [Related]
20. The pathological association between the anterior eye segment and the retina in a murine model of neovascular glaucoma.
Nishinaka A; Tanaka M; Aoshima K; Kuriyama A; Sasaki T; Otsu W; Yasuda H; Nakamura S; Shimazawa M; Hara H
FASEB J; 2022 Jun; 36(6):e22323. PubMed ID: 35485981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
